Ivermectin long acting injectable - Medincell
Alternative Names: mdc-STM; mdc-TTGLatest Information Update: 10 Sep 2024
At a glance
- Originator MedinCell S.A.
- Developer MedinCell S.A.; Monash University
- Class Antimalarials; Antineoplastics; Antiparasitics; Antivirals; Macrolides; Skin disorder therapies; Small molecules
- Mechanism of Action Chloride channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
- No development reported Malaria
Most Recent Events
- 03 Sep 2024 MedinCell plans a phase I clinical trial for Malaria in 2025
- 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Australia (SC, Injection)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Malaria in France (Injection)